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REPORT TO PHYSICIANS

Bladder Cancer Genetic Mapping
Effort Builds on Human Genome Project
by Kathryn L. Hale

waited to
see what
the Human
Genome Project would reveal ,
Bogdan Czerniak, M.D. ,
Ph.D ., a pathologist at The
University of Texas M. D.
Anderson Cancer Center, had
already found an application
for it.
Under Dr. Czerniak's direction, a
collaborative study now under way at
M. D. Anderson and oth er Texas
Medical Center institutions is combining clinicopathologic information from
patients with bladder cancer with
Human Genome Project data to create
a unique genetic map of the diseasea map that researchers hope will lead
them to the prevention and earlier
detection of bladder cancer.
Like many other solid tumors,
bladder cancer has proved a challenge
to clinicians. Despite continual refine( Continued on next page)

Dr. Bogdan Czerniak, an associate professor in the Department of Pathology , and

his colleagues are using histologic studies and genetic mapping to identify target genes that
may be markers of bladder cancer in its very earliest stages.
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Bladder Cancer
(Continued from page 1)
ments in treatment strategies, mortality
rates from the disease have remained
fairly stable over the years. Patients
whose disease is detected and treated
early tend to have a better chance of
achieving remission and living longer
than patients whose cancer is advanced
by the time it is diagnosed. The emphasis in cancer research, therefore, is not
only improving therapies but also
improving prevention and early
detection strategies.
These strategies have focused largely
on exploiting the stepwise progression
of neoplastic changes typical of solid
tumors. In the progression of tissue
from normal to frankly neoplastic are a
number of predictable microscopic
precancerous changes detectable by
histologic studies. It makes sense that
once these changes are recognized, they
become targets for interventions that
could stop the cancerous progression at
that point. Some now believe, hbwever,
that even these microscopic precancerous changes represent a point too far
along in the progression to stop the
cancer from developing. Markers of
earlier changes are needed, and Dr.
Czerniak is looking for them.
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Combining histologic
and genetic mapping
Dr. Czerniak and his team began by
mapping the histologic changes associated with bladder cancer. They took
multiple bladder wall samples from a
series of patients with bladder cancer
and precisely mapped the locations of
various preneoplastic cell changes from
mild dysplasia to carcinoma in situ.
They then analyzed DNA from these
samples and, by using known genetic
markers, painstakingly searched,
chromosome by chromosome, for loci
of allelic deletion (a potential genetic
precursor of cancer) using now-standard
polymerase chain reaction amplification
and high-resolution gel techniques.
Correlation of this DNA analysis with
the "whole organ" histologic mapping
identified which of these loci were
associated geographically with cancerous tissue changes. Said Dr. Czerniak,
"This allowed us to narrow down our list
of loci of interest from hundreds to about
90 and yielded a preliminary genetic map
2 / OncoLog
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Abbreviations : cM = cenrim01gan ; SHGM = superimposed histologic and generic maps;
LOD = logarithms of odds; NU = nonnal urothelium; LO IN = low-grade intraurothelial neoplasia;
HGIN = high-grade intraurothelial neoplasia; TCC= transitional cell carcinoma.

This map shows the minimally deleted regions on chromosome 2 (far left column) that are
involved in the progression of bladder neoplasia. Genome-wide data on bladder cancer progression can be obtained from the Web site www.rrulanderson.org/departments/genomemaps .
of bladder cancer. But these loci were
only rough estimates of the exact genes
involved in cancer development."
About 30% of these 90 markers are
associated with hist_ologically normal
tissue in the cancerous bladder. Besides
confirming that genetic changes precede
histologic changes in the development
of tumors, this yielded a potential set of
targets for very early intervention in

bladder cancer prevention.
The next step was to identify more
precisely the regions of DNA that were
altered in these cancers. This is where
the Human Genome Project came in.
Under the direction of Steven Scherer,
Ph.D., of the Human Genome Sequencing Center at Baylor College of Medicine, the "physical map" of human
DNA forged by the Human Genome

Project-which comprised genetic
sequences of a series of overlapping
DNA fragments anchored by known
hypervariable markers-was combined
with the preliminary genetic map
generated in Dr. Czerniak's lab, and the
genetic sequences associated with the
loci of interest were identified.
"This project, this opportunity,
would not exist without the Human
Genome Project," asserted Dr. Czerniak.
"We are definitely following in its
foo tsteps." The project, which is part
of the nearly $10 million Specialized
Programs for Research Excellence
(SPORE) grant for bladder cancer
recently awarded to M. D. Anderson,
is a natural extension of the massive
Human Genome Project, which is
nearly complete. Dr. Scherer said,
"This project is a clear demonstration
that the Human Genome Project is not
an ending but a beginning. It is providing basic tools that can be applied to
solve any genetic problem."

Using microarray technology
to speed identification of
target genes
Defining the associated genetic
sequences was a significant achievement, but the sequences themselves
are not exact enough for clinical
application. Only the specific altered
sequences can serve as markers of
disease, and further analysis was necessary to pinpoint these target genes. The
process of locating specific genes among
larger sequences is a laborious one.
However, a relatively new technology
called microarray analysis has emerged
to hasten, if not simplify, this process.
Microarray analysis uses complex
hybridization techniques to compare
patient DNA with clones generated
from Human Genome Project sequencing data. This allows very precise
identification of specific genetic
sequences that have been lost or altered.
Many fragments can be analyzed at one
time, telescoping the time needed to
generate gene targets. Using DNA
fragments supplied by Dr. Czerniak's lab,
a group at the Human Genetics Center
of The University of Texas School of
Public Health led by Li Jin, Ph.D.,
processes the microarrays. At first

glance, Dr. Li, a population geneticist,
may seem an odd choice to run this arm
of the project, but he said that when
Dr. Czerniak approached him three
years ago with his idea for analyzing
large numbers of DNA samples, "I got
the link right away. For this project,
I treat populations of cells just like they
were populations of humans."
Said Dr. Czerniak, "The microarray
technique is easy to explain but technically difficult to implement. It actually
maps the target genes from very small
DNA fragments." Although microarray
technology is gaining a foothold in
genetics research, it is still very much in
development. Recalled Dr. Li, "The
application had to be customized, which
meant both constructing the hardware
and writing the software. It took nearly
two years to develop and has been
operational for almost a year. It was very
much a trial-and-error process, and we
nearly gave up a few times." Added Dr.
Czerniak, "Only in the past few months
have we been able to process the
number of samples we need to process.
We are now generating huge amounts of
usable data. Our knowledge is exploding, and we're just getting started." The
final step in the process is confirmation
of the microarray findings by fluorescence in situ hybridization back at
M. D. Anderson.

Testing preliminary markers
What does the team plan to do with
the target genes they have identified?
Dr. Czerniak's lab has received almost
$2.3 million from the Early Detection
Network, a National Cancer Institutesponsored network of laboratories that
cooperate to identify markers for early
cancer detection. As his team identifies
target genes, other labs in the network
will validate their applicability as
markers in the clinical setting. Said Dr.
Czerniak, "The basic objective of the
project is to move cancer detection from
the clinical to the preclinical or occult,
histologically undetectable phases of
cancer progression and to extend this
capability to a number of different
cancers. We want to learn how to
identify these cancers on the molecular
level and use that knowledge to develop
novel concepts of cancer prevention."

He continued, "Every lab in the
Early Detection N etwork is using its
own unique approach. No one else is
doing exactly what we are doi'ng.
Obviously, we think this approach
will get us to our ultimate goal, which
is simple, noninvasive screening tests
that will identify cancers in their very
earliest stages." Bladder cancer is an
ideal candidate for such tests because
the bladder is a relatively accessible
organ; moreover, urine is the ideal
medium for noninvasive testing.
Previous tests have indicated that loci
of allelic deletion are detectable in the
urine of at least some patients with
bladder cancer. Dr. Czerniak hopes that
eventually his work will lead to the
development of tests that are both
practical for screening large groups of
people and reliable in detecting early
bladder cancers.
Preliminary clinical trials are already
under way. Seven regional markers of
bladder cancer identified in the preliminary phase of Dr. Czerniak's project are
being used in a trial funded by the
SPORE grant to test chemopreventive
strategies for preventing recurrences in
patients who have been treated for
bladder cancer and are without disease.
The effectiveness of the seven markers
in detecting early recurrences is being
examined. "These seven markers were
among the most consistent across all
patients tested. More markers will be
added to the study as they are developed," reported Dr. Czerniak. "The
overall goal is to identify at least five
markers with good clinical applicability."
Dr. Czerniak is confident that the
research strategy he is helping to
develop will eventually provide a key
to understanding the evolution of
genetic alterations in the progression
of neoplastic disease. He reacts with
consternation when asked whether
the project is too big, too complex.
"Cancer is a form of life," he counters.
"Do not expect it to be simple." •
FoR MORE INFORMATION ,

contact

Dr. Czerniak at (713) 794-1025 .
See page 4 for bladder cancer
protocols.
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Clinical Trials for Bladder Cancer
Clinical trials in progress at The
University of Texas M. D. Anderson Cancer
Center include the following for patients
w ith cancers and precancers of the bladder
and urothelium.

•

•

•

Random ized chemoprevention trial
with fenretinide (4-HPR) in superficial
bladder cancer (ID95-236) . Physician:
H. Barton Grossman, M.D.
Patients in this phase Ill trial must
have solitary or multifocal superficial
transitional cell carcinoma of the
bladder that is either newly diagnosed
or secondary in patients who have
been primary tumor-free for more
than a year. Newly diagnosed bladder
tumors must have been resected less
than four weeks prior to study entry.
Women must not be pregnant at the
time of enrollment and must comply
with mandatory contraceptive measures during the trial and for one year
after termination of the drug.
Methotrexate, vinblastine, doxorubicin,
and cisplatin (MVAC) in organ-confined
bladder cancer based on p53 status
(URL98-141) . Physician: Colin Dinney,
M.D.
Patients with potentially curable,
organ-confined bladder cancer are
eligible for this multicenter phase Ill trial
of chemotherapy with methotrexate,
vinblastine, doxorubicin, and cisplatin
(MVAC) . Patients must register for the
trial within nine weeks of a radical
cystectomy and bilateral pelvic lymphadenectomy and must not have
received any prior systemic chemotherapy or pelvic irradiation.
Phase II surgical consolidation for
subdiaphragmatic retroperitoneal and
pelvic lymph node metastases following
response to chemotherapy in patients
with transitional cell carcinoma of the
bladder and node-only disease (ID96193). Physician: Louis Pisters, M.D.
Patients with histologic proof of
predominantly transitional cell carcinoma of the bladder and histologic
proof of nodal disease may enroll if
they have a life expectancy of more
than six months. Patients are excluded
if they have local soft tissue recurrence
or evidence of distant metastasis in the
bone, lungs, viscera, or brain or nodes
outside the subdiaphragmatic
retroperitoneum or the pelvis. This
inpatient surgical procedure requires
a five- to seven-day stay in Houston
with follow-up visits every th ree months
thereafter.

4 I OncoLog

•

•

•

lntravesical AD -32 treatment of
superficial bladder cancer characterized on the basis of the tumor markers
p53 and pRb (ID97-038). Physician:
Colin Dinney, M.D.
Patients with recurrent stage Ta or T1
transitional cell carcinoma, newly
diagnosed multifocal transitional cell
carcinoma, or stage T1 transitional cell
carcinoma are eligible. Participants
must have no evidence of upper tract
(ureter or renal pelvic) transitional cell
carcinoma. Previous treatment with
intravesical AD-32 or with any intravenously administered systemic chemotherapy for bladder cancer is not
allowed. Patients who are being treated
with other chemotherapeutic agents ,
biological response modifiers, radiation
therapy, or hormonal therapy or who
are planning to receive such therapy
during the study period will not be
eligible.
A randomized multicenter phase Ill trial
evaluating the efficacy and safety of the
BCI immune activator versus doxorubicin in BCG-refractory or BCG-intolerant
patients with carcinoma in situ with
or without resected superficial papillary
bladder cancer (URL99-009).
Physician: H. Barton Grossman, M.D.
Participants in this outpatient
protocol must have carcinoma in situ
of the bladder that has not been treated
with intravesical therapy in the four
weeks prior to enrollment, radiation
therapy in the four months prior to
enrollment, or cystectomy. Patients
must not have been previously treated
with doxorubicin and may not be
treated concurrently with any chemotherapeutic drug during the trial. To
be eligible, patients must also have
disease refractory to or be intolerant
of BCG.
A phase I trial of intravesical adenovirus p53 treatment in locally advanced
and metastatic bladder cancer (DM96172). Physician: Lance Pagliaro, M.D.
Enrollment criteria include histologically confirmed transitional cell carcinoma of the bladder with muscle
invasion or lamina propria invasion,
unresectable local-regional disease
or asymptomatic distant visceral
metastases, bidimensionally measurable disease, and a life expectancy of
more than 12 weeks. Patients must be
HIV-negative and must not have
received any prior gene therapy.

•A

randomized phase II selection trial
of four chemotherapy regimens in
urothelial cancer (ID99-393) . Physician:

Randall Millikan, M.D. , Ph.D.
Eligible patients must have histologic
proof of metastatic or locally unresectable predominantly transitional cell
carcinoma of the urothelium . Participants must also have a life expectancy
of at least nine months based on
comorbidity and at least eight weeks
based on the natu ral history of their
cancer. Exclusion criteria include a
clinical history of heart disease and
pelvic irradiation in the six weeks prior
to study enrollment.

•

•

Phase II trial of ifosfamide and doxorubicin alternating with VP-16 and
cisplatin fo r small cell carcinoma of
the urothelium (DM00-039). Physician:
Randall Millikan, M. D. , Ph.D.
Patients with histologically confirmed
small cell carcinoma of the urothelium
will be considered for this inpatient trial
requi ring an initial 2 1-day stay in
Houston and subsequent follow-up
every six weeks. No clinically or
radiographically measurable disease
is needed for patients with bladderonly cancer. For those with metastatic
disease, at least one site must be
measurable. Patients must not have
been previously treated for metastatic
disease but may have been treated
with chemotherapy in some instances.
Phase II evaluati on of bladder preservation in TO, Ta, Tis, and T1 bladder
cancer after chemotherapy (URL96005). Physician: Colin Dinney, M.D.
This trial is designed for patients
with invasive bladder cancer that has
responded well to systemic chemotherapy. Patients must have a documented complete response in all
metastatic sites and normal or minimal
bladder-wall thickening in the primary
site . Those with urothelial carcinoma
of the renal pelvis , ureter, urethra, or
prostate will be excluded, as will those
treated for a prior malignancy (unless
they have been disease-free for at least
five years) . •

FoR MORE INFORMATION about these clinical
trials , physicians or patients may call the
M . D. Anderson Information Line . Those
within the United States should call (800)
392-161 1; those in Houston or outside the
United States should call (713) 792-6 161.
Visit the M. D. Anderson Cancer
Center clinical trials Web site at http://
www.clinicaltrials. org for a broader listing
of treatment research protocols .

INFORMATION SHEET IS YOURS TO COPY AND PASS ON TO PATIENTS.

Overcoming Barriers to
Cancer Screening for Men
ar ly detection of
cancer has saved
thousands of lives,
yet we all have a
tendency to put off getting the
recommended cancer screening
tests. Societal pressures can make
it especially difficult for men to
take part in testing and follow
cancer screening guidelines.
In general, men are less likely than
women to participate in important
preventive health activities, according
to Leslie R. Schover, Ph.D., an associate
professor in the Department of Behav
ioral Science at M. D. Anderson Cancer
Center. "Men in our culture are brought
up with the male stereotype to be strong,
uncomplaining, and tough," said Dr.
Schover. "For many men, a checkup is
a sign of weakness. They may even wait
until a health emergency to see a doctor."
Bernard Levin, M.D., vice president
for cancer prevention at M. D. Ander
son, said that some men are embarrassed
by examinations of the rectum, or they
fear the possible physical discomfort of
the tests. They may also worry that
surgery for pelvic cancer, such as
prostate or colorectal cancer, could
cause sexual dysfunction. (This is a
valid concern; however, many men are
able to stay sexually active after these
treatments, either because they recover
good sexual function or with the help
of medical treatments.)
The American Cancer Society
estimates that if all Americans had the
recommended early detection testing,
the five-year survival rate for people
with colorectal, prostate, testicular,
mouth, and skin cancers would increase
to 90% or higher. In addition, the
treatment for earlier-stage cancers is
often less aggressive and more successful
than that for advanced cancers. The
following screening exams are recom
mended for men.

If yo u or s omeo ne you know is relucta nt t o get screened forca ncer,
try the following suggest io ns:
1. Read and understand

the specific benefits of
cancer screening.

2. Check out your insur
ance benefits, or take
advantage of free cancer
screenings.
3. Make an appointment to
see your physician and
discuss your screening
options.

'---■_P_ r_o_ s _ta_ t_ e_ s_c_r_e_en_ _in--=g=---_____JI

I ■ Sk in exams

I ■ Colorectal screening

These simple exams can save a man's
life-provided he takes advantage of
them. For more information about
cancer screening and prevention, call
the M. D. Anderson Cancer Prevention
Center at (800) 438-6434. •

M. D. Anderson recommends an
annual digital rectal examination (a
health professional inserts a gloved
finger into the rectum and feels the
prostate gland for abnormalities) and
a prostate-specific antigen blood test
for men ages 50 to 70 who have a life
expectancy of at least 10 years and
who have been counseled and understand the risks of screening.

Starting at age 50, men should have
both a yearly fecal occult blood test,
which checks for signs of blood in the
stool, and a flexible sigmoidoscopy, an
exam of the rectum and lower colon
using a lighted instrument, every five
years. Done at home, the fecal occult
blood test requires the client to take
small samples of three consecutive
bowel movements and then mail the
results to a lab. Other options for
colorectal screening are a colonoscopy,
an exam of the rectum and entire colon
with a lighted instrument, every 10
years or a double-contrast barium
enema every five years. For the latter
test, a series of x-rays are taken after
the patient is given an enema with a
barium solution that outlines the
colon and rectum on the x-rays.

Beginning at age 18, men should
check for a mole or freckle that has
jagged borders, color that isn't uniform,
or a diameter larger than a pencil eraser.
These changes or any new, colored skin
growth should be reported to a physician for further testing. Skin checks
should be part of a regular physical
given by a doctor.

For more information, contact
your physician or contact the
M. D. Anderson Information Line:
({) (800) 392-1611 within
the United States, or
({) (713) 792-6161 in Houston
and outside the United States.
June 2001
©2001 The University of Texas
M. D. Anderson Cancer Center

Keeping in Touch: Office of Physician
Relations Builds Partnerships, Maintains
Contact with Community Physicians
by Dawn Chalaire

oday, physicians
from around the
world can refer their
patients for treat~
ment at The University of
Texas M. D. Anderson Cancer
Center without ever setting foat
on the campus of the Houston,
Texas, facility . But rapid growth
at the center-fueled, in part,
by an increase in referrals-has
been a mixed blessing. While
more and more patients are
receiving the specialized care
that they need, personal contact
between community physicians
and the institution's faculty is
becoming more difficult .
The ch allenge of providing community doctors with a face to go along with
the M. D. Anderson name is being met
by the Office of Physician Relations.
Through visits by physician relations
coordinators, exhibits at major medical
meetings, and educational events,
representatives of M. D. Anderson and
its faculty h ave the opportunity to meet
with community physicians in person to
build partnerships that are vital to the
center's battle against cancer.
"As a tertiary care center, we are
dependent upon referrals from the outside
to survive," said Richard J. Babaian, M.D.,
a professor in the Department of Urology
and co-medical director of the Office of
Physician Relations. "We have to learn as
a group to be more available and responsive to physicians who are helping us take
care of patients. We may not be the
patient's only doctor. That is where the
concept of partnering with them becomes
very important."
6 I OncoLog
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Lori Lund, a
ph:,sician relation ·
coordinator in th
Office of Physicia11

Relations, visit.
with Dr. Richard
Baltz, a medi al
oncologist and
M. D. Anderson
etwark Phy:, um
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At M. D. Anderson, 56% of patients-an average of more than 35
per day-are referred by or at the advice
of their physicians. Luis Campos, M.D.,
a medical oncologist and community
medical director of the M. D. Anderson
Physicians Network, said that he refers
patients to M. D. Anderson when their
disease calls for treatments that he
cannot provide, when a second opinion
is needed to establish the diagnosis,
or when the patient requests it.
Since 1996, the number of admission
to the institution has risen by 12%, while
the number of outpatient visits has risen
by 3 7%. More patients often means
longer waits for initial patient appointments and busier faculty members who
can be more difficult to get in touch
with, said Lewis Foxhall, M.D., associate
vice president for health policy and comedical director of the Office of Physician Relations, which also monitors the
referral process and responds to complaints or requests fo r help.

"M
"th r
r

all a1cl.
ly, but
ru.

1
•

them
one at
th
be t oluti n w can."
According t L
vice pre id nt fi r
enr
in the Office of Ph
,
the two is ue that are m t important
to community phy ician are patient
acce s and communication. Dr. Campo
echoed that a e ment, aying that
when phy ician are attenti e to the
referring doctor, the referral proce is
very ea y. He added that a lack of
integration between the clinic and
the bu ines office ometime create
headaches for patient . "Ideall , the
clinical part hould be integrated
with the financial part, e pecially for
international patients," Dr. Campo
said. M. D. Ander o · · fact hifting
from a centralized bu
office and

referral center to business offices and
referral centers located within each
care center, a move that is expected
to streamline the process of making
appointments. The institution has also
implemented a document management
system that automates much of the
transcription and feedback process so
that reports can be sent to the referring
doctors more quickly, efficiently, and
consistently.
Joseph Kong, M.D., an adjunct
associate professor of radiotherapy at
M. D. Anderson, who also has a private
practice, said that promptness is the
most important characteristic of a good
referral experience. Dr. Kong said that
he prefers to refer patients by phone,
and ideally, he would like "to make one
phone call and be able to tell the
patient when their appointment is
before they leave my office."
To gauge the success of the referral
process, the Office of Physician Relations asks all referring physicians to
complete a survey about their experience after each patient referral. Among
other questions, the survey asks physicians to rate their level of satisfaction
with M. D. Anderson when it comes to
the assistance they received in obtaining financial authorization fo r their
patient and the timeliness of feedback
about the patient.
"There is also an opportunity for
physicians to make suggestions to the
faculty about what they might do better
or change to make the process more
effective," Dr. Foxhall said. "The survey
is based on a particular referral, so we
can give feedback to the care center
that the community doctor was working
with."
"Several times a year, we go over
referral activity information with the
faculty and administrative leadership in
each center so they understand their
physician referral base," Green added.
"We also present feedback information,
and we will provide them with quarterly
reports on the satisfaction survey."
One way that referring physicians
can help the institution keep them
informed, Green said, is by reminding
patients whom they h ave directed to

call M. D. Anderson for an appointment to provide
the referring
physician's name
and address as the
follow-up doctor.
Having accurate
and complete
contact information about a
patient's physician
Dr. Lewis Foxhall (left), co-medical director of the Office
is essential to
of Physician Relations, and Lyle Green, assistant vice
enabling M. D.
president for referral development, work to build partnerships
Anderson's
between.M. D. Anderson and physicians in the community.
information and
document management systems to link
of Physician Relations also attend major
the referring physician to the patient
medical society meetings, where they
meet with physicians in private practice,
record.
Besides responding to requests for
sharing news from the institution and
information and assisting with the
receiving feedback. Often, faculty
referral process, the Office of Physician
members spend time at the exhibit
Relations promotes communication
booth, meeting with other physicians
between M. D. Anderson and commuand answering questions. The office is
nity physicians through several proexploring opportunities to contact
grams and activities.
referring physicians in the communities
where the meetings are held as a means
Physician relations coordinators
meet individually with doctors in their
of establishing personal relationships
offices in Houston and the surrounding
with physicians outside of the region
where office visits are currently made.
area, answering questions, discussing
Green emphasized that the Office of
areas of concern, and sharing with
them information about new services,
Physician Relations welcomes calls from
programs, or clinical trials available to
physicians and has an oncology nurse
on staff to answer specific, clinically
them or their patients.
oriented questions about clinical trials.
"Because our faculty have limited
"If community physidans have a
opportunity to meet with the clinical
problem or an issue they want to talk to
community physicians on a regular
us about, or if they need some information
basis, our staff helps to bridge the gap
about a clinical trial they can't find on our
there and serves as a liaison between
Web site, we would be more than happy
the institution and the doctors out in
to work with them," Dr. Foxhall said. "We
the community," Dr. Foxhall said.
want them to be aware that if there is a
The office also works with local
problem, we really want to hear about it
hospitals and other interested groups
and work with them to correct it." •
to offer cancer education programs and
faculty-led continuing medical educaFoR MORE INFORMATION about the Physition (CME) classes to doctors in the
cian Relations program at M. D. Anderson
community. Richard Baltz, M.D., a
medical oncologist and M . D. Anderson or to contact a Physician Relations coordinator, please call (713) 792-2202 or
Network Physician, said that he
(800) 252-0502 or send an e-mail to
attends CME classes sponsored by
physicianrelations@mdanderson.org.
M. D. Anderson as often as possible.
Community physicians and their office
"These are very good resources
for community oncologists to utilize,"
staff are encouraged to visit the
Dr. Baltz said.
Physician Relations Web site at http://
Representatives from the Office
www.mdanderson.org/physicianrelations.
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About These Clinical
Pradice Guidelines

The Developers

These guidelines may assist in the
diagnostic evaluation of patients with
clinical symptoms or positive screening
tests (if such testing exists) . The clinician is expected to use independent
medical judgment in the context of
individual clinical circumstances
to determine any patient's care.
M . D. Anderson Cancer Center's
Practice Guidelines are continually
updated as new information becomes
available and are being expanded to
include the entire spectrum of cancer
management. New guidelines for
screening and diagnosis are currently
under development. Access the most
current version of all M. D. Anderson
Practice Guidelines from M. D.
Anderson's Home Page at http://
www.mdanderson.org.

Richard E. Champlin,
M.D.
Chairman and
Professor of Medicine
Department of Blood
and Marrow
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Continuing Medical Education:
An expanded version of these
materials with CME category 1
credit is available on the Internet.
Access Practice Guidelines from
M. D. And erson's Home Page at

http://www.mdanderson.org.

Maria A. Rodriguez,
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Associate Professor
of Medicine
Department of
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Richard B. Wilder,
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Radiation Oncology
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CLINICAL
DISCUSSION:
Diffuse Large B-Cell
Lymphoma
Scope of This Guideline
Non-Hodgkin's lymphoma (NHL)
represents as many as 30 biologically
different diseases. These en tities are
currently classified according to the
Revised European-American Classification system, although work is
currently under way to develop a
system that better reflects the clinical
behavior and natural history of the
.various NHL subtypes. Some subtypes
of NHL share common diagnostic
and treatment elements, and therefore the treatment guidelines for
some subtypes of NHL may apply to
others. The guideline presented here
addresses the evaluation, treatment,
and fo llow-up care of patients who
have diffuse large B-cell lymphoma,
a clinically aggressive and commonly
occurring subtype of NHL. Other
NHL subtypes are addressed in
separate guidelines, as are those
occurring in patients with HIV.
Hodgkin's disease is considered a
separate category of lymphoma and
is also addressed in its own guideline.

Synopsis & Highlights
Overview
Non-Hodgkin 's lymphomas are a
heterogeneous group of m alignancies
that usually present in lymphoid
tissues (e.g., lymph nodes, spleen , and
bone marrow) but can arise in almost
any tissue. The most common extranodal sites are the stomach, skin,
oropharynx, small intestine, and
central nervous system. Their multicentricity and pattern of spread
distinguish these neoplasms from
Hodgkin 's disease: NHL tends to
spread early, and widely, in noncontiguous rather than orderly lymphatic
patterns. The most important d eterminant of outcome, h owever, is not
the extent of spread but rather the
histological classification. The lowgrade histologic subtypes, which
include small lymph ocytic and
follicular lymphomas, tend to h ave
a slow-growing, or indolent, disease
course. Relapses are common and
may occu r after several years. The
"curability" of patients with those
lymphomas is therefore controversial.
Diffuse large B-cell lymphoma, on the
oth er hand, is considered aggressive,
and yet paradoxically, approxim ately
half of the patients with this disease
subtype are considered curable with
standard therapy. This is becau se the
tendency to grow quickly renders the
(Continued on next page)

(Continued from previous page)

disease more responsive to chemotherapy and radiotherapy. If these
lymphomas relapse, they tend to do
so quickly (within 2 to 3 years).
The treatment approach for
diffuse large B-cell lymphoma is
multimodal, with combination
chemotherapy as the mainstay.
Radiotherapy (XRT) is also recommended for patie nts with localized
disease that has responded to chemotherapy and for those who have
advanced bulky disease. Peripheral
stem cell transplanta tion is used to
treat relapsing or unresponsive
disease.
Initial Evaluation
Correct identification of the
histologic subclassification is central
to the successful treatment of lymphomas. All lymphoma guidelines,
therefore , begin with a diagnostic
and staging evaluation that includes
a careful morphologic examination
of lymph node or tumor tissue biopsy
samples and in many cases, immunophenotyping and molecular analysis.
Close coordination with a hematopathologist experienced in lymphoma
is recommended. The biopsy should
be excisional; pathologic diagnosis of
lymphoma relies on the analysis of
architectural alterations, so core
needle biopsy and fine-needle
aspiration (FNA) may not be adequate. In cases where an excisional
biopsy is not possible, a core needle
biopsy with two or three samples is

preferable to FNA. Optimally, the
most clinically significant site should
be biopsied and an intact lymph node
removed and delivered as a fresh
specimen for pathologic examination.
Staging
Once the lymphoma is histologically classified, further staging is
appropriate for determining a
treatme nt approach. It is important
to evaluate and document the extent
of disease, beginning with a thorough
history and physical examination. As
a le uke mic blood phase may occur in
some lymphomas, hematologic and
bone marrow studies are indicated,
which may include histochemical
staining, immunophenotyping,
cytogenetic analysis, and in some
cases, molecular genetics.
Imaging studies may be indicated
by physical findings and presentation
and m ay include x-rays, computed
tomography (CT), positron e mission
tomography (PET) , and gallium
scans, which can be useful in differe ntiating fibrotic tissue from a viable
tumor. The prese nting symptoms may
indicate additional studies to evaluate
disease extent (e.g., bone or gastrointestinal studies) .
The Ann Arbor classification system
for NHL is based on the location and
distribution of lymphatic and nonlymphatic organ involvement. The
M. D. Anderson tumor score, i\ke
the International Prognostic Index,
considers the Ann Arbor stage along
with other facto rs tha t reflect tumor
burden and correlate with prognosis.

Lymphoma (All Types): Diagnosis and Staging (1)
DIAGNOSIS

STAGING EVALUATION

The tumor score is d erived by assigning one point for each of the following conditions:
•

a lactate dehydroge nase (LDH)
level elevated~ 10% above normal
• a beta 2 microglobulin (B 2M) level
~ 3.0 (i.e.,~ 1.5 times the upper
limit of normal)
• a tumor m ass ~ 7 cm in maximum
dimension
• the prese nce of secondary systemic
("B") symptoms consisting of
unexplained fevers, dre nching
night sweats, or> 10% weight loss
over the preceding 6 months
• Ann Arbor stage III or IV disease
Patients with diffuse large B-cell
lymphoma who present with tumor
scores of 0 to 2 h ave a 5-year overall
expected survival rate of 60% to 85%;
this rate drops to approximately 20%
to 40% for those with scores of 3 or
higher.
Initial Treatment
The goal of initial treatment is to
achieve a complete remission . According to Dr. Rodriguez, this subtype of
NHL has been shown to be a rapidly
progressing disease for which the
m edian duration of survival if untreated or unresp onsive to treatment
is 1 to 2 years. H owever, long-term
disease-free survival and cure have
been achieved in a high percentage
of patients with a tumor score of 0 to
2 using combina tion chemothe rapy
followed by involved-field rad iotherapy. Currently, the most widely

used chemotherapy regimen is the
CHOP regimen, a combination of
cyclophosphamide (Cytoxan),
doxorubicin (Adriamycin), vincristine
(Oncovin), and prednison e. For
patients more than 60 years of age,
the monoclonal antibody rituximab
(Rituxan) is added to this combination (R-CHOP).
Patients who present with localized
disease (tumor score Oto 2, Ann Arbor
stage 1-11) are treated with three cycles
of CHOP (R-CHOP for patients older
than age 60) chemotherapy, followed
by a response evaluation in which
previously positive tests for tumor
presence are re peated. For patients
who have a complete response to
CHOP or R-CHOP, involved-field
XRT is recommended, particularly
in localized-stage disease where an
abbreviated number of chemothe rapy
cycles is given. According to Dr.
Wilder, the XRT dose is tailored to
the size of the tumor before chemotherapy: a dose of 30.0-30.6 Gy is used
for tumors< 3.5 cm in diameter, 39.6
Gy for tumors 3.5-10.0 cm, and 45.0
Gy fo r tumors > 10 cm . If the response to CHOP or R-CHOP therapy
appears to be incomplete, a gallium
scan is indicated, and if the residual
mass is found to be gallium-positive,
a biopsy is recommended. If the
biopsy is positive, indicating persistent
active lymphoma, high-dose chemotherapy and a peripheral blood stem
cell transpla nt are recommended; if
th e biopsy is n egative, involved-field
XRT is the recommendation.
Patients with a tumor score of O to 2
who have bulky disease, stage III-IV
disease, or slowly responding tumors are
treated initially with six courses of
CHOP (or R-CHOP) chemotherapy.
This is followed by either XRT or by
stem cell transolantation (with nr
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Complete history and physical exam

Excisional lymph node
biopsy - special tissue
handling required

Blood work:
CBC , differential, platelets, Na. K, Cl , CO2 , total protein ,
BUN/creatinine , calcium , phosphorous , alkaline phosphatase ,
uric acid, glucose, SGOT, total bilirubin , serum protein electrophoresis,
H IV, LOH, and Beta 2 microglobulin (B 2 M)

Hematopathology
consultation

I

~

\
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without XRT) , depending upon the
response, as outlined above.

I Chest x-ray (posterior-anterior and lateral)

Patients who present with advancedstage disease (tumor score 2_ 3) are
I

less likely to be cured with standard
therapy and are best treated in
clinical trials using new regimens.
In one such study at M. D . Anderson
(DM95-121), patients are treated with
either high-dose chemotherapy and
stem cell transplantation or with an
aggressive chemotherapy program
of three alternating non-crossresistant chemotherapy regimens.

• , P_athologic
d1agnos1s

CT scan of neck
CT scan of abdomen and pelvis
Bone marrow biopsy/aspirate, bilateral echocardiogram/MUGA scan
Gallium scan or PET scan
If indicated by abnormal test or presenting symptoms:
Coombs and haptoglobin if anemic
CT scan of chest if CXR is abnormal
Endoscopy, upper GI , barium enema
Bone scan or skeletal films if bone pain

Ver:Compass/3/2/#1

□ Treatment

Diffuse Large B-Cell Lymphoma (2)
INITIAL TREATMENT

RESPONSE
Repeat
positive studies

Tumor
score*
_
02

Tumor

score*
"3

{

CONSOLIDATION/
ADDITIONAL
THERAPY

RELAPSE

Clinical trial or

Age ,; 60: CHOP x 3 cycles
Age > 60: CHOP + Rituxan
x 3 cycles

Ann Arbor

"''" "
Ann Arbor
stage Il l-IV,
bulky or
slowly
responding
disease

I

Complete
response

Field-involved XRT,

r

or
CRU ..

dose dependent
on initial tumor size
(30-45 Gy)

-----If

Clinical trial or
Age ,; 60: CHOP x 6 cycles
Age > 60: CHOP + Rituxan
x 6 cycles

►

I

Clinical trial or if not eligible

.. I

I

• 1 C\urveillance

• Clinical trial or

I

• , • Stem cell transplant" ..

I

.,

Complete
response

I- or • Clinical trial or
Partial
CRu••
IIMI • Stem cell transplant ...
orno ----<►
+/-XRT
response

Clinical trial

I

Age ,; 60: CHOP x 6 cycles
Age > 60: CHOP + Rituxan
x 6 cycles

• Tumor score= (1 point per factor):
• LDH ~ 10% above normal
• 82M ~ 3
• Bulky disease (.e 7 cm mass)
• B symptoms present
• Ann Arbor stage Ill/IV
•• CRU = Complete response unconfirmed (76% to 99% reduction in tumor size)
••• Stem cell transplant:
Autologous recommended if patient responded well to previous therapy.
Allogeneic recommended if multiple recurrences or poor response to previous therapy.
CHOP= cyclophosphamide (Cytoxan) , doxorubicin (Adriamycin), vincrisline (Oncovin), prednisone

or no
response

Surveillance:
Follow-up with comprehensive exam every 3 to 4 months
for 2 years, then every 6 months for 1 year, then annually.
Include CT scan and bone marrow biopsy (if initially
positive) annually for 5 years.

Long-term management includes screening for second
malignancies (e.g., breast, prostate, skin, colorectal).

Ver.Compass/'J/2/#2

M . D . Anderson's Practice Guidelines were developed l7y multidisciplinary teams of physicians and nurses and are intended to represent evidence-based cancer care with
consensus of opinion used secondarily. The core development team for this guideline included Dr. Richard E. Champlin, Dr. Maria A . Rodriguez, and Dr. Richard B. Wilder.

Relapse
The management of recurrent
disease is largely directed by the
response to earlier therapy. Other
influencing factors are the patient's
age and performance status, the
extent of recurrent disease, and the
duration of remission. Response is
assessed on the basis of a clinical
examination and a CT scan. A bone
marrow aspiration and biopsy is
performed only if a previous one
was positive or if it is indicated by the
appearance of new abnormalities.
A complete response (CR) is defined
as the complete disappearance of
all detectable evidence of disease
(clinically and radiographically),
including normalization of biochemical abnormalities. An unconfirmed
complete response (CRU) is a 76% to
99% regression in tumor size, and a
partial response (PR) requires a 50%
to 75% decrease in the size of the
six largest dominant nodes or nodal
masses plus a > 50% regression in
splenic and hepatic nodules, with
no new sites of disease. Relapse is
defined as the appearance of any new
lesion or an increase in the size of a
previously identified node or lesion
by> 50%.
In cases of partial or no response
to earlier therapy, treatment with an
allogeneic nonmyeloablative peripheral blood stem cell transplant has
produced encouraging results.
According to Dr. Champlin, this
procedure, sometimes called a mini
(Continued on next

page)

(Continued from previous page)

transplant, is less toxic than a standard "high-dose" bone marrow
transplant. Stem cell transplantation
consists of the intravenous administration of stem cells, preceded by highdose chemotherapy. The main
purpose of the prior chemotherapy is
to suppress the recipient's immune
response to prevent rejection of the
transplant, but it also reduces the
tumor burden. Allogen eic transplants
confer a graft-versus-lymphoma effect
in which the donor's immune cells
eradicate the lymphoma. Autologous
transplantation is less effec tive but has
a lower risk of complications, and
therefore it is chosen in favorable
cases (first relapse, good response
to initial therapy) and in cases where
the pa tien t is not able to tolerate the
stronger treatm ent. An allogeneic
transplant is recommended in more
difficult cases, such as those involving
multiple recurrences or poor responses
to prior therapies. Clinical trials are
highly recommended in this setting.
Surveillance
When an aggressive lymphoma
relapses, it usually does so within 2 to 3
years, so frequent follow-up evalua tions
are recommended after treatment.
The risk of developing a secon d
malignancy is high er for p a ti ents who
have been treated for NHL, so vigilant
screen ing for oth er cancers is part of
the long-term management of these
patients and shou ld include:

•

Mammography. Wome n who have
undergon e rad iotherapy to the
breasts should have a baselin
mammogram startin g at age 40 (or
10 years posttreatment if they were
less than 30 years o ld at the time
of irradiation). Mammography
should be repeated an nually or
as needed.

• A prostate-specific antigen test for
men beginning at age 50 and
repeated annually until age 70
• A baseline colonoscopy, yearly
fecal occult blood test, and appropriate work-up for all patients
starting a t age 50
• Skin examinations for all patients
yearly
• A chest x-ray annually
• A urinalysis annually, esp ecially
if treated with high-dose cyclophosphamide
• Thyroid function studies for
patients who have unde rgone
radiotherapy to the neck
In addition, adult vaccines for
influenza, hepatitis, and pneumococcus as recommended by the Centers
for Disease Control are indicated,
especially for patients who have
undergon e splenectomy.

Authors' Perspectives
Despite the fairly high cure rate for
patients with this subtype of NHL, it is
important to develop therapies that
are less toxic and more effective. In
addition, the ongoing development
of immun oth erapeutic strategies such
as vaccines, DNA antisense molecules,
an d monoclon al antibodies makes it
imperative th at we continue to
reassess previously held concep ts
of accepted treatrnen t strategies.
For this reaso n , it is important to
consider clinical trials as the preferred choice for all stages and
subtypes of NHL.
Find more information about
clinical trials and current protocols
available at M . D. Anderson at
http://www. mdanderson. org/researrh/.

References a Suggested Reading
Ch eson B, H o rnin g S, Coiffier, et al. Report of
an internatio nal workshop to standardize
respon se criteria for non-Hodgkin's
lym ph omas.] Clin Oncol 17: 12441253,1999
Gascoyn e R. Establishing the di agnosis of
lym ph oma: From initial biopsy to cl inical
staging. Oncology 12(Suppl 8) :11-16, 1998
Harris NL,Jaffe ES, Stein H , et al. A revised
European-Am e rican classification of
lymphoid neoplasms: A proposal from the
Intern ation al Lymphoma Study Grou p.
Blood 84: 1361-1 392, 1994
Melnyk A, Rod riguez MA. Intermediate- and
high-grade no n-Hodgkin 's lymphomas.
In Medical Oncology: A Com preh ensive
Review, Pazd ur R (ed). PRR In c.,
Huntington NY, pp 99-110, 1995
Moore D, Caban illas F. Overview of prognostic
factors in non-Hodgkin's lymph oma.
Oncology 12(Suppl 8):17-24, 1998
Murphy G, Lawrence W, Lenhard R. American
Cancer Society Textbook of Clinical Oncology, 2nd

ed. American Cancer Society, pp 45 1-467,
1995
NCCN Practice Guide lin es for Non-Hodgkin 's
Lymphomas, Version 2000. Oncology.June
2000
Rodrig uez ] , Cabanillas F, McLaughlin P, et al.
A proposal for a simple stagin g system for
intermed iate-grade lymphoma and
immunoblastic lymphoma based on the
'tumor score.' Ann Oncol 3:711-717, 1992
Wi lder RB, Rod,·iguez MA, H a CS, et al. Bulky
disease is an adverse prognostic factor in
patie nts treated with chemotherapy
comprised of cyclophosphamide, doxorubicin , vincristine and prednisone with or
without rad iotherapy for aggressive
lym phoma. Cancer 9 1 (12) :2440-2~2001
Wi lder R, Rodriguez MA, Tucker SL, et al.
Radiation therapy after partial respon~
Lo CHOP chemotherapy for aggressive
lymphomas. In t] Radial Oncol Biol Phys
50(3):743-749, 2001

'aSS
Quarterly Supplement to Oncol.og
Produced by the Department of Scientific Publications
for the Practice Outcomes Program

Ronald S. Walters, M .D .
Medical Director, Care Management Program,
M. D. Anderson Cancer Center and
Medical Director, Managed Care Programs,
M. D. Anderson Physicians Network"'

Academic Programs
Margaret Kripke, Ph.D.
Senior Vice President and Chief Academic Officer

Stephen P. Tornasovic, Ph .D.
Vice President for Educational Programs

Managing Editor
Julia M. Starr, B.A.
D epartmenl of Scientific Publications

Contributing Editor
Sunni H osem an n , R.N., B.S.N.
Educational Programs

Design
Mataya Design
Chart Illustrations
Sunn i Hosernann, R.N., B.S. N.
©2001 The University of Texas M. D. Anderson
Cancer Center

l ndividual.s should not rely exclusively on information
contained in these clinical guidelines. H ealth care
providers must use their own professional judgment in
treating patients. Individual.s should not substitute
these guutflines for professional 1ru,dical advice,
diagnosis, 1or treatment and should consult a qualified
physician if they have medical questions or concerns.
The University of Texas M. D. Anderson Cancer

Cent'& makes 110 warranti.es or representations,
erpressed or imp lied, as to the accuracy, completem,ss, or us'efi,lness of th e i,ifonnation contained or
referenced in the clinical guidelines and disclaims
any and all liability for i,yury and/or other damages
to any third party resultingfro11, any individual's
following these guidelines.

